Aviva
VKTX icon

Aviva’s Viking Therapeutics VKTX Stock Holding History

Aviva’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-207,322
Closed -$1.31M – 983
2021
Q1 		$1.31M Buy
207,322
+18,496
+10% +$130K 0.01% 748
2020
Q4 		$1.06M Sell
188,826
-153,076
-45% -$927K 0.01% 853
2020
Q3 		$1.99M Buy
341,902
+27,322
+9% +$188K 0.01% 782
2020
Q2 		$2.27M Sell
314,580
-280,121
-47% -$1.86M 0.01% 731
2020
Q1 		$2.78M Buy
+594,701
New +$3.66M 0.02% 668

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aviva's VKTX Position: Q2 2021 in Review

Aviva sold out of Viking Therapeutics (VKTX) in Q2 2021, closing a stake of 207,322 shares — an estimated $1.31M sold.

Aviva first reported a position in VKTX in Q1 2020 and held it in 5 quarters. The position peaked at $2.78M in Q1 2020. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2021.

  • Aviva reported no remaining Viking Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Aviva sold 207,322 Viking Therapeutics shares in Q2 2021, an estimated $1.31M.
  • Aviva first reported a position in Viking Therapeutics in Q1 2020 and held it in 5 quarters.
  • Aviva's Viking Therapeutics position peaked at $2.78M in Q1 2020.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.